In conclusion, the present study has revealed the novel finding that PS positive L-EVMreg can suppress both CD4+ and CD8+ T-cells, suggesting the potential clinical use of L-EVMreg in various diseases associated with increased T-cell activity, including multiple sclerosis, rheumatoid arthritis, type 1 diabetes, allergic reactions, and transplant rejection. The gene discussed is CD8A; the disease is type 1 diabetes mellitus.